Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy

Leukemia

Volumn 29, Issue 2, 2015, Pages 441-447

  Nelson, A S ^a,b   Ashton, L J ^c   Vajdic, C M ^d   Le Marsney, R E ^b   Daniels, B ^d   Nivison Smith, I ^e   Wilcox, L ^e   Dodds, A J ^f   O'Brien, T A ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Australasian Bone Marrow Transplant Recipient Registry   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUSTRALIAN; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CHILD; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECIPIENT; SECOND CANCER; THYROID CANCER; ADVERSE EFFECTS; AUSTRALIA; COMPLICATION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; RECURRENT DISEASE; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; AUSTRALIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RISK FACTORS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84922487953     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.203     Document Type: Article

References (25)

1. Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348-357.
2. Baker KS, Defor TE, Burns LJ, Ramsay NK, Neglia JP, ROBISON LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358.
3. Schechter T, Pole JD, Darmawikarta D, Doyle J, Ali M, Egeler M et al. Late mortality after hematopoietic SCT for a childhood malignancy. Bone Marrow Transplant 2013; 48: 1291-1295.
4. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DD, Moore JJ et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905-912.
5. Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464-471.
6. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-1183.
7. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
8. Cohen A, Rovelli A, Merlo DF, Van Lint MT, Lanino E, Bresters D et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol 2007; 25: 2449-2454.
9. Cohen A, Rovelli A, Van Lint MT, Merlo F, Gaiero A, Mulas R et al. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood. Bone Marrow Transplant 2001; 28: 1125-1128.
10. Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-392.
11. Kolb HJ, Socie G, Duell T, Van Lint MT, Tichelli A, Apperley JF et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738-744.
12. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
13. Hemminki K, Jiang Y, Steineck G. Skin cancer and non-Hodgkin's lymphoma as second malignancies: markers of impaired immune function? Eur J Cancer 2003; 39: 223-229.
14. Guerin S, Dupuy A, Anderson H, Shamsaldin A, Svanh-Tapper G, Moller T et al. Radiation dose as a risk factor for malignant melanoma following childhood cancer. Eur J Cancer 2003; 39: 2379-2386.
15. Corpron CA, Black T, Ross MI, Herzog CS, Ried HL, Lally KP et al. Melanoma as a second malignant neoplasm after childhood cancer. Am J Surg 1996; 172: 459-462.
16. Chou RH, Wong GB, Kramer JH, Wara DW, Matthay KK, Crittenden MR et al. Toxicities of total-body irradiation for pediatric bone marrow transplantation. Intl J Radiat Oncol Biol Phys 1996; 34: 843-851.
17. Ferry C, Gemayel G, Rocha V, Labopin M, Esperou H, Robin M et al. Long-term outcomes after allogeneic stem cell transplantation for children with haematological malignancies. Bone Marrow Transplant 2007; 40: 219-224.
18. Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ et al. Long-term follow-up of children who underwent hematopoietic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 2007; 49: 958-963.
19. Davies SM, Ramsay NKC, Klein JP, Weisdorf DJ, Bolwell B, Cahn J-Y et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340-347.
20. Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17: 197-207.
21. Eapen M, Ahn KW, Orchard PJ, Cowan MJ, Davies SM, Fasth A et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transplant 2012; 18: 1438-1445.
22. Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1316-1326.
23. Eapen M, Rubinstein P, Zhang M-J, Stevens C, Kurtzberg J, Scaradavou A et al. Outcomes of transplantation of unrelated donor umbilical cord and bone marrow in children with acute leukemia: a comparison study. Lancet 2007; 369: 1947-1954.
24. Gluckman E, Rocha V. on behalf of the EBMT Paediatirc, Acute Leukemia Working Parties and Eurocord. Indications and results of cord blood transplant in children with leukemia. Bone Marrow Transplant 2008; 41: S80-S82.
25. Sauter C, Barker JN. Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies. Curr Opin Hematol 2008; 15: 568-57.